Confronto
DSIP vs. FOXO4-DRI
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
62568-57-4
2074706-72-8
Peso molecolare
848.81 g/mol
3735 g/mol
Emivita
0.1 h
0.5 h
Sequenza
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluD-Retro-Inverso-Variante eines FOXO4-Peptid-Fragments (LTLRKEPASEIAQSILEAYSQNGWANRRSGGKR — D-Aminosäuren in umgekehrter Sequenz)Meccanismo d'azione
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
FOXO4-DRI
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Modello animale
Studi
4
3
di cui sull'uomo
1
0
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between DSIP and FOXO4-DRI?
- DSIP is classified as "Ricerca (altro)", while FOXO4-DRI is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. FOXO4-DRI: Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senolytic candidate. Goal: selective apoptosis of senescent cells via disruption of the FOXO4-p53 interaction. So far evaluated exclusively preclinically. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or FOXO4-DRI?
- The highest available evidence level is "Studio sull'uomo" for DSIP and "Modello animale" for FOXO4-DRI. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and FOXO4-DRI in Germany and the United States?
- Germania: DSIP — Non approvato, FOXO4-DRI — Solo ricerca. Stati Uniti: DSIP — Non approvato, FOXO4-DRI — Solo ricerca. These are factual summaries with source and review date on the individual pages.